Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Dysregulation of Fibroblast Growth Factor Receptor (FGFR) signaling through amplifications, mutations, and gene fusions has been implicated in a broad array of cancers (e.g. liver, gastric, ovarian, endometrial, and bladder). ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibito...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2016-09, Vol.11 (9), p.e0162594-e0162594
Hauptverfasser:	Hall, Terence G, Yu, Yi, Eathiraj, Sudharshan, Wang, Yunxia, Savage, Ronald E, Lapierre, Jean-Marc, Schwartz, Brian, Abbadessa, Giovanni
Format:	Artikel
Sprache:	eng
Schlagworte:	AKT protein Amplification Aniline Compounds - pharmacology Animals Antineoplastic Agents - pharmacology Apoptosis Biliary tract cancer Biology and Life Sciences Biotechnology Bladder Blotting, Western Cell cycle Cell Cycle - drug effects Cell Line Cell proliferation Cell Proliferation - drug effects Chlorocebus aethiops Cholangiocarcinoma COS Cells - drug effects COS Cells - physiology Endometrium Enzyme inhibitors Extracellular signal-regulated kinase Female Fibroblast growth factor Fibroblast growth factor receptor 1 Fibroblast growth factor receptor 2 Fibroblast growth factor receptors Fibroblast growth factors Fibroblasts Genetic aspects Growth factors Inhibitors Kinases Liver Lung cancer Medical research Medicine and Health Sciences Metastasis Mice, Nude Mice, SCID Mutation Neoplasm Transplantation Neoplasms - drug therapy Oncology Ovarian cancer Phosphorylation Proteins Quinazolines - pharmacology Receptors, Fibroblast Growth Factor - antagonists & inhibitors Signal transduction Signaling Tumors Urinary bladder Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!